Scourboutakos, Adjunct Lecturer in Family and Community Medicine, University of Toronto
PubMed Heffernan, M.A., Thorburn, A.W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M.J., & Ng, F.M
Cardiovascular safety data from published trials showed reductions in systolic blood pressure (ranging from 4.3 to 7.9 mmHg depending on dose) and diastolic blood pressure (2.3 to 4.6 mmHg reductions)
Even then, the magnitude of the effect we observed was so large that this will most likely stand the test of time and represent a meaningful improvement in ablation outcomes for the strategy of adjunctive and riskfactor modification when applied before the procedure, as done in LEAF
These foundational approaches address the root causes of insulin resistance and hormonal imbalances that drive PCOS symptoms
In studies with healthy subjects, sitagliptin did not lower blood glucose or cause hypoglycemia